140408-84-0 Usage
Uses
Used in Pharmaceutical Industry:
(S)-(-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is used as an intermediate in the synthesis of biologically active molecules for various therapeutic applications. Its unique structure and reactivity make it a valuable compound for the development of new drugs.
Used in Drug Formulation:
In the pharmaceutical industry, (S)-(-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is used as a compound to improve the solubility and stability of pharmaceutical formulations. The hydrochloride salt form of (S)-(-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride allows for better dissolution and stability, which is crucial for the effectiveness and safety of medications.
Used in Research and Development:
(S)-(-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is utilized as a subject of research and development in the pharmaceutical industry. Its potential applications and the possibility of creating new biologically active molecules make it an attractive candidate for further investigation and innovation.
Check Digit Verification of cas no
The CAS Registry Mumber 140408-84-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,0,4,0 and 8 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 140408-84:
(8*1)+(7*4)+(6*0)+(5*4)+(4*0)+(3*8)+(2*8)+(1*4)=100
100 % 10 = 0
So 140408-84-0 is a valid CAS Registry Number.
140408-84-0Relevant academic research and scientific papers
Pagé,Naismith,Schmidt,Coupal,Labarre,Gosselin,Bellemare,Payza,Brown
, p. 2387 - 2390 (2001)
The design, synthesis and pharmacological evaluation of a novel class of Dmt-Tic dipeptide analogues are described. These resulting analogues bearing different C-terminal functionalities were found to bind to the human δ receptor with high affinity. One s
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
, (2008/06/13)
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent
